C. difficile 위험도


Usual doseHAP3.375 g (Piperacillin/tazobactam 3/0.375 g) IV q6h4.5 g (Piperacillin/tazobactam 4/0.5 g) IV q6h

Safety and efficacy in pediatric patients <12y of age have not been established- Age 2m-9m 90 mg/kg IV q8h

  • Age >9m 112.5 mg/kg IV q8h

  • BW >40 kg Refer to adult doseThere are no dosing recommendations for pediatric pts with renal impairment

No dose adjustment

CrCl >40CrCl 20-40CrCl <20HDCAPDCRRT3.375 g IV q6h2.25 g IV q6h2.25 g IV q8h2.25 g IV q12h + additional 0.75 g IV AD2.25 g IV q12h2.25 g q6h

CrCl >40CrCl 20-40CrCl <20HDCAPDCRRT4.5 g IV q6h3.375 g IV q6h2.25 g IV q6h2.25 g IV q8h + additional 0.75 g IV AD2.25 g IV q8hMIC≤16: 3.375 g (over 30m) q6h MIC>16-64: 4.5 g (over 4h) q8h

General Information

Broad spectrum agent with anti-pseudomonal activity

Used for severe infections including:

  • Pneumonia

  • Intra-abdominal/hepatobiliary

  • UTI

  • Polymicrobial skin and soft tissue infection

  • Febrile neutropenia

Assess hematopoietic function periodically, including differential.

Monitor electrolytes periodically.

Closely monitor patients with renal impairment or seizure disorders for signs and symptoms of neuromuscular excitability or convulsions.

  • Allergy/rash (immediate or delayed)

  • Cytopenias- esp. thrombocytopenia

  • Eosinophilia

  • Interstitial nephritis

  • Abnormal liver enzymes

Multiple major drug-drug interactions

  • Amifampridine

  • Bupropion

  • Tetracyclines

  • Donepezil

  • Methotrexate

  • Vancomycin

  • Vecuronium

  • Warfarin

  • Cholera vaccine, live

Antimicrobial class: Ureidopenicillin, Beta-lactamase inhibitor

Pregnancy category: B

Average serum half life: 1 hour

Urine penetration: Therapeutic

Lung penetration: Therapeutic

CSF penetration: Poor

Biliary penetration: Therapeutic


  • Use caution in patients with renal failure or cystic fibrosis.

  • Use caution in patients requiring sodium restriction.

  • Discontinuation of antibacterial use not directed against Clostridium difficile may be required.

  • Monitoring recommended in prolonged therapy; discontinue if bleeding manifestations occur.

  • Monitoring recommended in patients with renal impairment or seizure disorder.

  • Increased risk of neuromuscular excitability or convulsions with higher than recommended doses.

Terms of Use | Feedback
© Copyright 2021 Spectrum Mobile Health Inc., dba Firstline Clinical. All rights reserved.